- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01938638
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
The purpose of this study Part A is to determine the safety, tolerability and the pharmacokinetics of BAY1143572 in subjects with advanced malignancies, which are either refractory to or ineligible for treatment with standard agents.
The purpose of this study Part B is:
Determine the safety, tolerability, pharmacokinetics (PK) and maximum tolerated dose (MTDG-CSF) of BAY1143572 with concurrent administration of the granulocyte colony-stimulating factors (G-CSF) in an intermittent and continuous dosing schedule in subjects with advanced malignancies.
Przegląd badań
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Seoul, Republika Korei, 110-744
-
Seoul, Republika Korei, 120-752
-
Seoul, Republika Korei, 05505
-
-
-
-
-
Singapore, Singapur, 119228
-
Singapore, Singapur, 169610
-
-
-
-
Arkansas
-
Fayetteville, Arkansas, Stany Zjednoczone, 72703
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
-
-
New Jersey
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
-
-
New York
-
New York, New York, Stany Zjednoczone, 10032
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
-
-
-
-
-
Taipei, Tajwan, 10002
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male or female subjects aged >/=21 years
- Dose escalation phase: Subjects with histologically or cytologically confirmed advanced malignancies (solid tumors and malignant lymphomas) who were refractory to or had exhausted all available therapies. Subjects had to have evaluable or measurable disease (as per RECIST 1.1 or Cheson 2007 criteria).
- Expansion phase only: Subjects with advanced, histologically or cytologically confirmed gastric cancer, triple negative breast cancer (TNBC), or diffuse large B-cell lymphoma (DLBCL), who were refractory to or had exhausted all available therapies. Subjects had to have evaluable or measurable disease (as per RECIST 1.1 or Cheson 2007 criteria).
- Archival tumor tissue to conduct molecular and / or genetic studies must be collected from all study subjects enrolled in this study.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Life expectancy of at least 12 weeks
- Adequate bone marrow, liver, and renal functions as assessed by laboratory analysis to be conducted within 7 days prior to the first dose of study drug
- International normalized ratio (INR) and partial thromboplastin time (PTT) </=1.5 times ULN (upper limit of normal)
Exclusion Criteria:
- Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
- History of cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months) or myocardial infarction within the past 6 months and cardiac arrhythmias requiring anti-arrhythmic therapy except for beta-blockers and digoxin; evidence for uncontrolled coronary artery disease (e.g. angina pectoris, myocardial infarction within 6 months prior to study entry, major regional wall motion abnormalities upon baseline echocardiography)
- Previous pulmonary embolism within 12 months prior to study entry
- Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg on 2 or more consecutive blood pressure readings, despite optimal medical management
- Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C
- Known history of human immunodeficiency virus (HIV) infection
- Chronic or active hepatitis B or C, requiring antiviral therapy
- Active clinically serious infections of > Grade 2 and/or active infections that require treatment with systemic agent
- Uncontrolled seizure disorder requiring therapy (such as steroids or anti-epileptics with significant CYP interaction)
- Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of > Grade 2 within 4 weeks prior to the first dose of study drug
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: BAY1143572 [continuous]
BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously
|
|
Eksperymentalny: BAY1143572 [on/off]
BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Liczba uczestników ze zdarzeniami niepożądanymi jako miara bezpieczeństwa i tolerancji
Ramy czasowe: Do 2 lat
|
Do 2 lat
|
|
Maximum tolerated dose (MTD) of BAY1143572
Ramy czasowe: Up to 1 year
|
In Part A: Maximum tolerated dose (MTD) of BAY1143572 In Part B; Maximum tolerated dose ( MTD) with G-CSF of BAY114357 The MTD is defined as the highest dose that can be given such that not more than 20% of subjects experience a dose limiting toxicity (DLT) during cycle 1.
|
Up to 1 year
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Maximum total drug concentration (Cmax)
Ramy czasowe: Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
|
Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
|
|
Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)
Ramy czasowe: Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
|
Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
|
|
Area under the plasma concentration-time curve from time zero to infinity (AUC)
Ramy czasowe: Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
|
Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
|
|
Time of maximum observed concentration (tmax)
Ramy czasowe: Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
|
Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
|
|
Tumor response based on RECIST 1.1 or Cheson 2007 criteria
Ramy czasowe: Up to 100 weeks
|
Up to 100 weeks
|
|
Biomarker evaluation by determination of MYC protein expression and PCNA mRNA
Ramy czasowe: Cycle 1, Day 1, Day 8 and Day 15 (each cycle is 28 days)
|
PCNA: proliferating cell nuclear Antigen mRNA: messenger ribonucleic acid
|
Cycle 1, Day 1, Day 8 and Day 15 (each cycle is 28 days)
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- 16519
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na BAY1143572
-
BayerZakończony